Therapy Guidance for Patients with Colorectal Cancer Discussed at NCCN Annual Conference
Highlights of the latest version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Colon and Rectal Cancer were presented at the NCCN 15th Annual Conference by Paul F. Engstrom, MD, of Fox Chase Cancer Center. Engstrom discussed specific recommendations for therapies and provided guidance on patients who benefit most from select regimens.
HOLLYWOOD, FL (March 11, 2010) – Despite statistics stating that colorectal cancer is the fourth most frequently diagnosed cancer in men and women in the United States, mortality from colon cancer has decreased slightly over the past 30 years, possibly because of earlier diagnoses through screening and better treatment modalities. Recommendations relating to the latest treatment options were recently highlighted by Paul F. Engstrom, MD - Acting Director, Hematology/Oncology, of Fox Chase Cancer Center and chair of the NCCN Guidelines Panel for Colon and Rectal Cancer at the NCCN 15th Annual Conference on March 11, 2010.
Dr. Engstrom discussed notable changes to the recently updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Colon and Rectal Cancer including the appropriate role of adjuvant therapy for colon cancer. He stressed that the NCCN Guidelines Panel does not endorse the use of bevacizumab (Avastin™, Genentech/Roche) or cetuximab (Erbitux®, Bristol-Myers Squibb/ImClone Systems) in the adjuvant treatment of patients with high risk colon cancer outside of a clinical trial.
“Patients with stage II colon cancer may be candidates for adjuvant chemotherapy based on poor prognostic features, pathologic findings, microsatellite instability, and possibly oncotype analysis,” said Dr. Engstrom.
Determination of tumor KRAS and BRAF gene status can be used for metastatic colorectal cancer prognosis and therapy evaluation and are referenced in the updated NCCN Guidelines.
Dr. Engstrom noted, “These molecular findings in a tumor continue to be important because they signal whether the use of epidermal growth factor receptor antagonists such as cetuximab and panitumumab (Vectibix®, Amgen) will be effective in treating a patient.”
BRAF analysis continues to be controversial since its impact in patients with KRAS wild type is not well studied. The updated NCCN Guidelines state that patients with a known V600E BRAF mutation appear unlikely to benefit fro anti-EGFR monoclonal antibodies - although the data are somewhat inconsistent.
The updated NCCN Guidelines also provide direction for patients who are being treated with the chemotherapy regimen FOLFOX, comprised of a combination of therapies including fluorouracil (FU), leucovorin (LV), and oxaliplatin (Eloxatin®, sanofi-aventis ).
Dr. Engstrom discussed that for patients with metastatic colorectal cancer who are being treated with FOLFOX and responding, but are experiencing symptomatic neuropathy, that the patient should discontinue oxaliplatin, but continue FU/LV without a significant drug holiday.
The criteria for transanal excision, a procedure for patients with rectal cancer that is designed to help retain bowel function, is carefully described in the NCCN Guidelines, however Dr. Engstrom stressed that it may not be a curative procedure in patients with T1-classified tumors because of the potential high recurrence rate and poor overall survival compared to more radical surgical procedures.
Neo-adjuvant therapy for select patients with rectal cancer, those with T1 or T2, N1 or N2 classified lesions, is strongly recommended as Dr. Engstrom stated, “Total regression of cancer in the post-radiotherapy specimen predicts an excellent disease-free survival.”
Additionally, Dr. Engstrom highlighted that patients who present with unresected primary tumor synchronous stage IV colorectal cancer benefit from combination chemotherapy and may not require palliative resection of the primary or bypass procedures.
Dr. Engstrom concluded stating that the NCCN Guidelines Panel believes that a multidisciplinary approach is necessary for managing colorectal cancer and that they strongly support the concept that treating patients in a clinical trial has priority over standard or accepted therapy.
The NCCN Guidelines are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent versions of all the NCCN Guidelines are available free of charge at NCCN.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
For more information, visit NCCN.org.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.